1 Min Read
June 12 (Reuters) - ALLIGATOR BIOSCIENCE AB:
* ALLIGATOR BIOSCIENCE HAS ADVANCED ANOTHER WHOLLY-OWNED CHECKPOINT MODULATOR PROGRAM, ATOR-1017, INTO PRE-CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.